Key Points
Hologic expects $1.09 EPS and $1.03B revenue on May 7, 2026.
Company beat EPS in two of three recent quarters but missed revenue twice.
B+ Meyka grade reflects solid fundamentals but valuation and growth concerns.
Investors should monitor segment performance, guidance changes, and margin trends.
Hologic, Inc. (HOLX) will report fiscal Q2 earnings on May 7, 2026, after market close. Wall Street expects the medical diagnostics and imaging company to deliver $1.09 earnings per share and $1.03 billion in revenue. The healthcare equipment maker has shown mixed results recently, beating EPS estimates in two of the last three quarters while missing revenue expectations. With a $16.97 billion market cap and stock trading near $76, investors are watching closely for signs of momentum in the company’s four key business segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
Earnings Expectations and Historical Performance
Analysts are forecasting steady performance from Hologic as the company navigates a competitive healthcare market. The $1.09 EPS estimate represents a slight increase from the prior quarter’s $1.04 actual EPS, signaling confidence in operational execution. Revenue guidance of $1.03 billion sits between recent quarters, suggesting stable demand across product lines.
Recent Quarter Trends
Hologic’s earnings history shows volatility in execution. In the most recent quarter (January 2026), the company beat EPS expectations by delivering $1.04 versus $1.09 estimate, but revenue came in at $1.048 billion versus $1.041 billion estimate. Two quarters prior (July 2025), HOLX exceeded EPS targets with $1.08 actual versus $1.05 estimate, though revenue missed at $1.024 billion versus $1.034 billion estimate. This pattern suggests the company manages profitability well but faces revenue headwinds.
Beat or Miss Prediction
Based on historical trends, Hologic appears more likely to meet or slightly beat EPS expectations while revenue could remain challenged. The company has beaten EPS in two of three recent quarters, demonstrating cost discipline. However, revenue misses in two consecutive quarters indicate market softness or competitive pressure in key segments. Investors should expect EPS near or slightly above $1.09, with revenue potentially ranging from $1.02 to $1.04 billion.
Key Business Segments and Growth Drivers
Hologic operates four distinct business segments, each facing different market dynamics. Understanding segment performance is critical for assessing earnings quality and future growth potential.
Diagnostics Segment Performance
The Diagnostics segment, featuring the Aptima molecular diagnostic platform, remains a core revenue driver. This segment includes tests for infectious diseases, including COVID-19 assays and viral load testing. While pandemic-related demand has normalized, the company’s molecular diagnostics portfolio continues generating steady cash flow. Investors should monitor whether this segment maintains pricing power and market share against competitors.
Breast Health and Surgical Growth
Breast Health and GYN Surgical segments represent growth opportunities in women’s health. The Breast Health division offers 2D and 3D digital mammography systems, biopsy guidance, and imaging analytics. GYN Surgical includes the NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. These segments benefit from aging populations and increased screening awareness, though capital equipment sales can be lumpy quarter to quarter.
Skeletal Health Expansion
The Skeletal Health segment, featuring the Horizon DXA system and Fluoroscan mini C-arm, addresses orthopedic and bone density markets. This segment has shown resilience as healthcare systems invest in diagnostic and surgical equipment. Watch for commentary on international expansion and market penetration in this division during the earnings call.
Financial Health and Valuation Metrics
Hologic’s balance sheet and valuation metrics provide context for earnings quality and investment risk. The company maintains solid financial footing despite recent earnings volatility.
Balance Sheet Strength
Hologic carries a debt-to-equity ratio of 0.48, indicating moderate leverage. The company maintains $10.54 in cash per share and a strong current ratio of 4.04, suggesting ample liquidity to fund operations and investments. Free cash flow per share stands at $4.45, providing flexibility for dividends, buybacks, or acquisitions. The company’s interest coverage ratio of 7.58 demonstrates comfortable debt servicing capability.
Valuation Assessment
At $76.01 per share, HOLX trades at a P/E ratio of 31.36, above the broader market average. The price-to-sales ratio of 4.11 reflects premium valuation typical of healthcare equipment manufacturers. However, the company’s net profit margin of 13.2% and return on equity of 11% justify some valuation premium. Earnings growth will be critical to supporting current valuations.
Meyka AI Grade Explanation
Meyka AI rates HOLX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ rating reflects solid fundamentals and market positioning, though the company faces growth headwinds and valuation concerns. These grades are not guaranteed and we are not financial advisors.
What Investors Should Watch During Earnings
The May 7 earnings call will provide crucial guidance on Hologic’s strategic direction and market conditions. Several items deserve investor attention.
Segment Revenue Breakdown
Management will detail revenue performance by segment. Watch for growth rates in Diagnostics versus Breast Health and Surgical divisions. Slower Diagnostics growth would signal normalization of pandemic-era demand, while weakness in Breast Health could indicate competitive pressure or delayed capital equipment purchases by healthcare systems.
Guidance and Outlook Commentary
Forward guidance is critical. Management commentary on international markets, product launches, and market share trends will shape investor sentiment. Any guidance changes, particularly revenue guidance, could trigger significant stock movement. Listen for discussion of pricing power, customer retention, and competitive dynamics.
Margin Trends and Cost Management
Operating margins and gross margins deserve scrutiny. The company’s ability to maintain profitability while investing in R&D and sales infrastructure will determine earnings sustainability. Watch for commentary on manufacturing costs, supply chain normalization, and operating leverage as volumes grow.
Final Thoughts
Hologic’s May 7 earnings report will test investor confidence in the company’s ability to deliver consistent growth. With $1.09 EPS and $1.03 billion revenue expected, the company faces a moderate bar based on recent performance. Historical trends suggest HOLX will likely meet EPS expectations while revenue remains a potential pressure point. The B+ Meyka AI grade reflects solid fundamentals but acknowledges valuation and growth concerns. Investors should focus on segment performance, forward guidance, and margin trends to assess whether Hologic can sustain its premium valuation. The stock’s 44% one-year gain has already priced in significant optimism, making execution critical.
FAQs
What EPS and revenue is Hologic expected to report on May 7?
Analysts expect Hologic to report $1.09 earnings per share and $1.03 billion in revenue, representing steady performance with EPS slightly above the January quarter’s $1.04 actual result.
Has Hologic beaten or missed earnings estimates recently?
Hologic beat EPS in two of the last three quarters but missed revenue expectations in two consecutive quarters, indicating strong cost management but potential revenue headwinds.
What is Meyka AI’s rating for HOLX and what does it mean?
Meyka AI rates HOLX with a B+ grade, reflecting solid fundamentals and market positioning. This suggests a neutral-to-positive outlook while acknowledging valuation and growth concerns.
What should investors watch during the earnings call?
Monitor segment revenue breakdown, forward guidance changes, margin trends, and management commentary on international markets, competitive dynamics, and product launches, as revenue guidance revisions historically move the stock.
Is HOLX stock fairly valued at current levels?
HOLX trades at P/E of 31.36, above market average. While the 13.2% net margin and 11% ROE justify some premium, earnings growth is critical to support valuations given the 44% one-year gain.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)